Terameprocol in Treating Patients With Recurrent High Grade Glioma
Status:
Active, not recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of terameprocol in treating
patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as
terameprocol, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Erimos Pharmaceuticals National Cancer Institute (NCI)